Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The metabolism of the structurally related 5HT3 antagonists ondansetron, alosetron and GR87442 in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes. The profiles of phase I metabolites were similar in human hepatocytes and microsomes. The metabolites of all three compounds produced in rat, dog and human microsomes and hepatocytes were similar to those seen in vivo, with the major routes of metabolism being N-dealkylation and/or hydroxylation. There was more extensive metabolic processing in hepatocytes than in microsomes; however, sequential metabolism was less extensive in vitro compared with in vivo. The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity. These data support the use of rat, dog and human hepatocytes for the prediction of in vivo metabolites of ondansetron, alosetron and GR87442.

Original publication

DOI

10.1080/00498250701485575

Type

Journal article

Journal

Xenobiotica

Publication Date

08/2007

Volume

37

Pages

832 - 854

Keywords

Animals, Carbolines, Chromatography, Liquid, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Enzyme System, Dogs, Hepatocytes, Humans, Kinetics, Male, Mass Spectrometry, Microsomes, Liver, Ondansetron, Rats, Rats, Wistar, Recombinant Proteins, Serotonin Antagonists